JNCI Journal of the National Cancer Institute最新文献

筛选
英文 中文
Cross-ancestry proteome-wide mendelian randomization of plasma proteins and breast cancer susceptibility. 血浆蛋白与乳腺癌易感性的跨祖先蛋白质组孟德尔随机化。
IF 7.7 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2026-11-14 DOI: 10.1093/jnci/djag447
Xueyao Wu, Devika Godbole, Jacob Williams, Jayati Sharma, Jiyeon Choi, Zhonghua Liu, Peter Kraft, Haoyu Zhang
{"title":"Cross-ancestry proteome-wide mendelian randomization of plasma proteins and breast cancer susceptibility.","authors":"Xueyao Wu, Devika Godbole, Jacob Williams, Jayati Sharma, Jiyeon Choi, Zhonghua Liu, Peter Kraft, Haoyu Zhang","doi":"10.1093/jnci/djag447","DOIUrl":"https://doi.org/10.1093/jnci/djag447","url":null,"abstract":"<p><strong>Background: </strong>The plasma proteome may help connect inherited breast cancer susceptibility to biologically interpretable and potentially actionable pathways, but proteome-wide evidence across ancestries remains limited.</p><p><strong>Methods: </strong>We conducted proteome-wide Mendelian randomization (MR) analyses of breast cancer risk using cis-protein quantitative trait loci for 1,962 distinct plasma proteins from 34,557 European-ancestry participants in the UK Biobank Pharma Proteomics Project. Breast cancer genome-wide association studies included 156,901 cases and 204,634 controls of European, East Asian, and African ancestries. Ancestry-specific MR estimates were combined by fixed-effects meta-analysis. Candidate proteins were further evaluated through subtype-specific and reverse-direction MR analyses, statistical colocalization, replication in independent European and East Asian proteomic datasets, and analyses of associations between protein polygenic scores and breast cancer status in All of Us.</p><p><strong>Results: </strong>Twelve proteins achieved Bonferroni significance in the cross-ancestry meta-analysis (P < 0.05/1,971 tests), including eight previously reported proteins and four newly prioritized by MR. DNPH1 showed cross-ancestry heterogeneity, while CASP8, RALB, and USP28 showed cross-subtype heterogeneity after accounting for shared controls (all P < 0.05/12). Complementary support varied: six candidates showed strong colocalization (PPH4 ≥ 0.80); four replicated with a consistent direction and nominal significance in deCODE, two in the Japan COVID-19 Task Force, and four in All of Us (all P < 0.05). The strongest cumulative support was observed for LRRC25, PARK7, and LRRC37A2.</p><p><strong>Conclusions: </strong>These findings prioritize circulating protein candidates for mechanistic, prevention-oriented, and translational follow-up in breast cancer, while underscoring the need for larger ancestrally diverse proteomic resources to support equitable target and biomarker discovery.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to Mokbel and Mokbel: SHBG and breast cancer risk in premenopausal women. 对Mokbel和Mokbel的反应:绝经前妇女SHBG和乳腺癌风险。
IF 7.7 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2026-11-14 DOI: 10.1093/jnci/djag434
Davide Serrano, Roberta Rizzo, Harriet Johansson, Aliana Guerrieri-Gonzaga, Sofia Ramalho, Andrea DeCensi, Sara Gandini
{"title":"Response to Mokbel and Mokbel: SHBG and breast cancer risk in premenopausal women.","authors":"Davide Serrano, Roberta Rizzo, Harriet Johansson, Aliana Guerrieri-Gonzaga, Sofia Ramalho, Andrea DeCensi, Sara Gandini","doi":"10.1093/jnci/djag434","DOIUrl":"https://doi.org/10.1093/jnci/djag434","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Operationalizing smoking cessation models of care in oncology settings: a mixed-methods systematic review. 在肿瘤学环境中实施戒烟治疗模式:一项混合方法的系统综述。
IF 7.7 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2026-11-13 DOI: 10.1093/jnci/djag418
Melissa T McEnallay, Melissa A Carlson, Nicole M Rankin, Fiona Day, Elena Stefanovska, Shalini K Vinod, Emily Stone, James McLennan, Christine L Paul
{"title":"Operationalizing smoking cessation models of care in oncology settings: a mixed-methods systematic review.","authors":"Melissa T McEnallay, Melissa A Carlson, Nicole M Rankin, Fiona Day, Elena Stefanovska, Shalini K Vinod, Emily Stone, James McLennan, Christine L Paul","doi":"10.1093/jnci/djag418","DOIUrl":"https://doi.org/10.1093/jnci/djag418","url":null,"abstract":"<p><strong>Background: </strong>Integrating smoking cessation care with cancer management is a pillar of high-quality care. However, implementation remains variable and little is known about how smoking cessation models are effectively operationalized in oncology settings.</p><p><strong>Objective: </strong>To describe the characteristics, adaptations, and operationalization of evidence-based smoking cessation models in oncology settings, and identify approaches to the definition, measurement, and evaluation of implementation outcomes.</p><p><strong>Methods: </strong>This systematic review followed JBI methodology. Five databases were searched to identify reports published between January 2010 and August 2025. Included reports described the implementation of evidence-based smoking cessation care models or process enhancements in hospitals or cancer services delivering care to people with cancer. Data sources were treated as complementary, synthesized separately, and integrated as a narrative summary.</p><p><strong>Results: </strong>Thirty-eight reports were included, identifying 33 implementation strategies and 38 models of care. Models of care included 3As (n = 18), 5As (n = 11), and 4As (n = 1) brief interventions, and specialist care models (n = 8). Nurses were commonly delegated to initiate smoking conversations (10/38) and facilitate referrals (17/38). Implementation strategies varied, however, education and training programs, and technology enhancements were commonly reported. Adaptation was a prominent feature and identified across most implementation strategies (24/33). Reporting and measurement of implementation outcomes was limited and not always aligned to a defined framework.</p><p><strong>Conclusions: </strong>Brief 3A models, nurse involvement, and opt-out referral pathways are core characteristics of smoking cessation care in oncology settings. Adaptation and tailoring components appear as a common feature of implementation strategies. Further reporting and evaluation of implementation outcomes is warranted.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Olanzapine or prochlorperazine added to antiemetic therapy for persistent chemotherapy-induced nausea: an NCORP phase 3 RCT. 奥氮平或丙氯哌嗪加入止吐治疗持续性化疗引起的恶心:NCORP 3期随机对照试验
IF 7.7 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2026-11-13 DOI: 10.1093/jnci/djag404
Luke J Peppone, Gary R Morrow, Riham Alieldin, Chunkit Fung, Michelle C Janelsins, Charles Kamen, Eva Culakova, Chin-Shang Li, Joseph J Guido, Kevin Spath, Jeremy McGuire, Katherine Reith, Belal Firwana, Thomas J Saphner, Samer S Kasbari, Joseph A Roscoe
{"title":"Olanzapine or prochlorperazine added to antiemetic therapy for persistent chemotherapy-induced nausea: an NCORP phase 3 RCT.","authors":"Luke J Peppone, Gary R Morrow, Riham Alieldin, Chunkit Fung, Michelle C Janelsins, Charles Kamen, Eva Culakova, Chin-Shang Li, Joseph J Guido, Kevin Spath, Jeremy McGuire, Katherine Reith, Belal Firwana, Thomas J Saphner, Samer S Kasbari, Joseph A Roscoe","doi":"10.1093/jnci/djag404","DOIUrl":"https://doi.org/10.1093/jnci/djag404","url":null,"abstract":"<p><strong>Background: </strong>Despite guideline-consistent antiemetic prophylaxis, persistent chemotherapy-induced nausea remains common, and comparative phase 3 evidence for olanzapine versus prochlorperazine is limited. We evaluated whether adding olanzapine or prochlorperazine to standardized Cycle 2 antiemetic prophylaxis reduces persistent nausea compared with placebo.</p><p><strong>Methods: </strong>In this multicenter, randomized, double-blind, placebo-controlled phase 3 trial at 23 NCORP community oncology sites (April 2018-January 2024), women 18 years or older with breast cancer receiving moderately or highly emetogenic chemotherapy who recorded a Cycle 1 nausea score of 3 or greater (1-7 scale) were randomized 1:1:1 during Cycle 2 to placebo, prochlorperazine (10 mg every 8 hours, Days 1-4), or olanzapine (10 mg once daily, Days 1-4), added to netupitant/palonosetron plus dexamethasone. The primary outcome was change in average nausea from Cycle 1 to Cycle 2; the key secondary outcome was change in maximum nausea.</p><p><strong>Results: </strong>Among 1363 screened patients, 310 comprised the intention-to-treat population (placebo, 91; prochlorperazine, 110; olanzapine, 109). Compared with placebo, average nausea improved with prochlorperazine (between-group difference, -0.44; P=.01) and olanzapine (-0.57; P=.001). Olanzapine reduced maximum nausea more than prochlorperazine (difference, -0.59; P=.02) and improved FACT-G quality-of-life scores over placebo (difference, 4.91; P=.006) and prochlorperazine (5.80; P=.001). Adverse events were primarily grade 1-2, with no toxicity-related discontinuations.</p><p><strong>Conclusions: </strong>Adding olanzapine or prochlorperazine to standardized Cycle 2 antiemetic prophylaxis reduced persistent chemotherapy-induced nausea compared with placebo. Olanzapine produced greater improvement in maximum nausea and quality of life than prochlorperazine and is an effective escalation option, with prochlorperazine a reasonable alternative when olanzapine is unsuitable.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT03367572.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Geographic Variation In Long-Term PM2.5 Exposure and Lung Cancer Incidence in the United States. 美国长期PM2.5暴露与肺癌发病率的地理差异
IF 7.7 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2026-11-13 DOI: 10.1093/jnci/djag442
Sara Myers, Elizabeth S Davis, Christopher Digesu, Kelly M Kenzik
{"title":"Geographic Variation In Long-Term PM2.5 Exposure and Lung Cancer Incidence in the United States.","authors":"Sara Myers, Elizabeth S Davis, Christopher Digesu, Kelly M Kenzik","doi":"10.1093/jnci/djag442","DOIUrl":"https://doi.org/10.1093/jnci/djag442","url":null,"abstract":"<p><strong>Purpose: </strong>A growing share of lung cancers occur in people who have never smoked, and air pollution may be one contributor. Inhalable particulate matter less than 2.5 um in diameter (PM2.5) has been linked to adverse health effects, but its role in lung cancer development across regions of the United States remains unclear.</p><p><strong>Methods: </strong>Lung cancer incidence from 2018-2022 (via Centers for Disease Control and Prevention) and annual average PM2.5 from 2005-2009 and 2010-2014 (via Area Health Resource File) were studied. Ordinary least squares (OLS) and geographically weighted regression (GWR) models were run, and models were compared using the corrected Akaike information criterion (AICc). Covariates included county-level poverty, racial makeup, educational attainment, and prevalence of smoking. Geographic distribution of PM2.5 levels was mapped to identify spatial clustering of higher and lower exposure (hot and cold spots) using the Getis-Ord Gi* statistic.</p><p><strong>Results: </strong>For both time windows, PM2.5 exposure was positively associated with lung cancer incidence. GWR models demonstrated improved model fit relative to OLS across both PM2.5 exposure periods (2005-2009: AICc 20,892 vs 21,810; 2010-2014: AICc 20,883 vs 21,847). Local GWR coefficient estimates for PM2.5 varied across counties, indicating spatial heterogeneity in the association between PM2.5 exposure and lung cancer incidence.</p><p><strong>Conclusion: </strong>The relationship between PM2.5 exposure and lung cancer incidence varies spatially, with different levels of risk in different counties. These exploratory findings show where the association appears stronger or weaker; they are a starting point for further study rather than a basis for county-specific interventions.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab. 更正:KRAS密码子特异性突变对加/不加贝伐单抗的trifluriddine -tipiracil治疗转移性结直肠癌患者生存的影响。
IF 7.7 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2026-11-12 DOI: 10.1093/jnci/djag367
{"title":"Correction to: Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab.","authors":"","doi":"10.1093/jnci/djag367","DOIUrl":"https://doi.org/10.1093/jnci/djag367","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Breast implant illness after reconstruction with silicone breast implants. 矫正:硅胶乳房植入物重建后的乳房植入疾病。
IF 7.7 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2026-11-12 DOI: 10.1093/jnci/djag405
{"title":"Correction to: Breast implant illness after reconstruction with silicone breast implants.","authors":"","doi":"10.1093/jnci/djag405","DOIUrl":"https://doi.org/10.1093/jnci/djag405","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing gastric cancer prevention in the United States: perspectives from a congressional forum. 在美国推进胃癌预防:来自国会论坛的观点。
IF 7.7 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2026-11-10 DOI: 10.1093/jnci/djag423
Chul S Hyun, Haejin In, Reetu Mukherji, Mu K Hong, Aki Smith, Joe McMenamin
{"title":"Advancing gastric cancer prevention in the United States: perspectives from a congressional forum.","authors":"Chul S Hyun, Haejin In, Reetu Mukherji, Mu K Hong, Aki Smith, Joe McMenamin","doi":"10.1093/jnci/djag423","DOIUrl":"https://doi.org/10.1093/jnci/djag423","url":null,"abstract":"<p><p>Effective strategies for gastric cancer prevention and early detection are available, yet they are not consistently implemented in the United States, particularly among populations at increased risk. As a result, many patients continue to be diagnosed with advanced disease despite opportunities for earlier intervention. A recent Congressional Forum brought together clinicians, researchers, patient advocates, and policymakers to examine barriers to translating established gastric cancer prevention strategies into routine practice. Integrating perspectives presented during the forum with published evidence and current clinical guidance, this Commentary presents a multidisciplinary, implementation-oriented policy framework addressing the clinical, informational, organizational, and access barriers that contribute to delayed diagnosis. Established approaches, including Helicobacter pylori testing and treatment, endoscopic detection of premalignant gastric lesions, and risk-based clinical assessment, provide a strong foundation for prevention but remain underused in routine practice. Building on this foundation, we propose practical policy priorities to improve implementation, including integration of gastric cancer risk assessment into routine clinical evaluation, incorporation of electronic health record based clinical decision support, and development of coordinated pathways for risk-based testing, referral, and surveillance. Advancing a national strategy that aligns prevention, clinical practice, and health policy has the potential to reduce disparities, promote earlier diagnosis, and improve gastric cancer outcomes in the United States.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
US geographical disparities in young-onset colorectal cancer mortality, 1990-2023. 1990-2023年美国年轻结直肠癌死亡率的地理差异
IF 7.7 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2026-11-10 DOI: 10.1093/jnci/djag420
James Fan Wu, Emma Ruoyi Zhang, Nishwant Swami, Erin Jay G Feliciano, Edward Christopher Dee
{"title":"US geographical disparities in young-onset colorectal cancer mortality, 1990-2023.","authors":"James Fan Wu, Emma Ruoyi Zhang, Nishwant Swami, Erin Jay G Feliciano, Edward Christopher Dee","doi":"10.1093/jnci/djag420","DOIUrl":"https://doi.org/10.1093/jnci/djag420","url":null,"abstract":"<p><p>Among the 5 leading causes of cancer death in people younger than 50 years in the US, colorectal cancer (CRC) is the only one with increasing mortality. Using Global Burden of Disease 2023 estimates, we examined young-onset CRC mortality among persons aged 15-49 years from 1990 through 2023. Age-standardized mortality rates (ASMRs) and Joinpoint trends were calculated, with change summarized by the 2014-2023 mean annual percentage change (APC). In 2023, the ASMR was 3.25 per 100,000 and varied more than twofold across states; the mean APC was 1.06%. Ten of 13 states in the highest ASMR quartile were in the South, whereas the fastest increases were in the West. Five hotspot states had both highest-quartile ASMR and mean APC: Alaska, Kentucky, Missouri, New Mexico, and Tennessee. Overall, 65.5% of deaths were jointly attributable to assessed GBD risks; behavioral and metabolic PAFs were 56.1% and 21.6%, respectively.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Occupational solar ultraviolet radiation exposure and incident ocular melanoma risk in two large-scale nordic cohorts. 职业性太阳紫外线照射和两个大型北欧队列的眼部黑色素瘤发病风险
IF 7.7 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2026-11-10 DOI: 10.1093/jnci/djag419
Michelle C Turner, Karina Undem, Muhammad Waseem Khan, Svetlana Solovieva, Damien M McElvenny, Zara Ann Stokholm, Calvin Ge, Vivi Schlünssen, Karl-Christian Nordby, Ingrid Sivesind Mehlum, Anjoeka Pronk, Henrik A Kolstad
{"title":"Occupational solar ultraviolet radiation exposure and incident ocular melanoma risk in two large-scale nordic cohorts.","authors":"Michelle C Turner, Karina Undem, Muhammad Waseem Khan, Svetlana Solovieva, Damien M McElvenny, Zara Ann Stokholm, Calvin Ge, Vivi Schlünssen, Karl-Christian Nordby, Ingrid Sivesind Mehlum, Anjoeka Pronk, Henrik A Kolstad","doi":"10.1093/jnci/djag419","DOIUrl":"https://doi.org/10.1093/jnci/djag419","url":null,"abstract":"<p><strong>Background: </strong>Solar radiation is a ubiquitous human carcinogen however its role in the etiology of cancer beyond melanoma and non-melanoma skin cancer is unclear. We sought to investigate the role of occupational solar ultraviolet radiation (UVR) exposure in ocular melanoma, a rare malignancy, using data from two large-scale Northern European cohorts.</p><p><strong>Methods: </strong>The Danish DOC*X cohort followed 2.95 million participants for a mean (SD) of 19.3 (11.2) years (1977 to 2015). The Norwegian Nor-Work cohort followed 2.45 million participants for a mean (SD) of 30.7 (13.6) years (1961 to 2020). Cancer cases were ascertained through national cancer registries. Lifetime cumulative occupational solar UVR exposure in terms of standard erythema dose (SED) was estimated using a novel European quantitative job-exposure matrix.</p><p><strong>Results: </strong>There were 233 incident ocular melanoma cases in DOC*X and 581 in Nor-Work. In DOC*X, there was little clear evidence for an association. In Nor-Work, adjusted incidence rate ratios (IRRs) were similarly elevated in the 2nd to 4th quartiles compared with the 1st (reference) quartile, being 1.80 (95% CI 1.12 to 2.92), 1.63 (95% CI 0.99 to 2.69), and 1.72 (95% CI 1.03 to 2.89), respectively (p-trend = 0.06) with an IRR per interquartile increase of 1.05 (95% CI 0.92 to 1.18). For uveal melanoma, IRRs among quartile categories were also elevated although weaker ranging from 1.35 to 1.45.</p><p><strong>Conclusions: </strong>We observed some non-monotonic positive associations of occupational solar UVR exposure and ocular melanoma particularly in Norway. Efforts to advance exposure assessment for large-scale studies are warranted.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书